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1. Introduction
Cancer has been traditionally seen as a disease characterized by many genetic alterations,
but recent studies have proven the implications of epigenetic abnormalities along carcino‐
genesis [1, 2].
The fundamental base of carcinogenesis is described by two major models: clonal evolution
and cancer stem cell (CSC) model [3-5].
In the past few years ‘cancer stem cells’ (CSCs) area has become an interesting field of cancer
research. In 19th century, Durante and Conheim [6] and after one hundred year Sell and
Pierce [6, 7] issued the hypothesis that stem cells could induce cancer in all type of tissues.
Unlike normal tissue stem cells, cancer stem cells are characterized by an abnormal differen‐
tiation rate, which can lead to tumor [8, 9].
The five principal factors, reported to be involved in carcinogenesis are:
• chemicals – John Hill, in 1761, was the first who showed that the chemicals agents pro‐
duce cancer of the nasal cavity [6];
• infections – Francis Peyton Rous was the pathologist awarded the Nobel Prize in Medicine
for his research that reported that the viral agents are involved in the origin of cancer [10];
• mutations – Theodor Heinrich Boveri and Von Hansemann argued the association be‐
tween development of cancer and abnormal mitoses [11];
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• teratocarcinomas – the field theory, which explains that in pathology of cancer are impli‐
cated a mixture of mature and differentiated cells and also embryonic tissue [12];
• epigenetic alterations – coerce to development of abnormal phenotypes, without any
structural changes of DNA [13];
The term epigenetic was introduced by Conrad Waddington in 1942, to explain the relation‐
ship between environment and genome. Model of „cancer stem cells” indicates that epige‐
netic changes occurred in stem or precursor cell are the earliest events that take place in
cancer [14].
There are two primary mechanisms involved in the epigenetic process: methylation of DNA
and covalent modification of histones [15].
DNA methylation is an inheritance mechanism, fundamentally important in normal devel‐
opment and cellular differentiation in mammalian organisms. This is a post-replication
DNA modification, by the addition of a methyl group to carbon 5 (C5] of the pyrimidine
ring of cytosines, predominantly in cytosine-phospho-guanine (CpG) dinucleotides.
In the eukaryotic cells, the pattern of methylation is the result of complex interactions be‐
tween three types of normal methylation processes: de novo methylation, the maintenance
of existing methylation and demethylation. DNA-methylation is catalyzed by several DNA
cytosine-5-methyltransferases (DNMTs), which can catalyse cytosine methylation in differ‐
ent sequence context. DNMT family include: DNMT1, which is responsible for methylation
maintenance  and DNMT3a and DNMT3b,  which  are  responsible  for  the  de  novo  DNA-
methylation [16].
The decisive developmental effect of DNA-methylation on gene expression is the long-term
silencing of gene expression. In human, the process of DNA-methylation is associated with
transcriptional silencing imprinted genes and X-chromosome inactivation. Both genomic im‐
printing and X-chromosome inactivation are suggested to regulate gene expression in em‐
bryonic and fetal growth.
Dysregulated normal imprinting is supposed to induce embryonic death and to impair fetal
growth. Defects in DNA-methylation process may also have major consequences for embry‐
onic development and are associated with congenital defects, autoimmunity, aging and ma‐
lignant transformation.
In recent years, the human methylation profile of the whole genome has been investigated
by DNA methylomic studies and altered DNA methylation has been found in cancer DNA
[2, 17] The transformation of normal cells into dysplastic and cancerous cells is due to a
broad range of genetic and epigenetic changes. Some of the epigenetic mechanisms of initia‐
tion and progression of cancer are strongly related to post translational modifications of his‐
tones, among which the methylation process is highly involved. The resistance of various
types of cancer to therapy led to the hypothesis that cancers present some cells, able to self
renew and differentiate into all types of cells that compose a tumor, named cancer stem cells
[8]. During embryonic development, characteristic patterns of CpG methylation are pro‐
duced in the different cell lineages that are then well conserved in normal adult cells, while
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in tumor cells, DNA methylation patterns become altered. A family of germline-specific
genes that use DNA methylation as a primary silencing mechanism, has been indicated as a
stem cells signature. These germline-specific genes expression in tumors, has also been hy‐
pothesised to reflect the expansion of constitutively expressing cancer stem cells [8].
Post-translational modification of histone proteins is an important area of regulation epige‐
netic. The post-translational modifications of the N-terminal tail domains include: methyla‐
tion, acetylation, phosphorylation, citrullination, ADP-ribosylation, sumoylation and
ubiquitination [18-20]. The most studied of these modifications are methylation and acetyla‐
tion. Modifications of histone N terminal ends by methylation and acetylation processes are
closely related to cancer and are done by the competition of two families of enzymes: his‐
tone acetyltransferases (HAT) and histone acetylases (HDAC). Lysine residues acetylation in
the histone H3 and H4 by (HAT and lysine 4 methylation in the histone H3 (H3K4me) by
histone methyltransferase (HMT) are generally correlated with active transcription of chro‐
matin. In contrast, methylation of lysine 9 and lysine 27 (H3K9, H3K27me) in the histone 3,
have been considered as markers in transcriptionally silenced-chromatin [21, 22].
Dysregulation of epigenetic mechanisms in stem cells may induce alteration in stem cells
function, (i.e. self-renewal and differentiation potential), leading to cancer initiation and pro‐
gression. During the last years, a major challenge in cancer biology is to elucidate how the
histone modifications in stem cells influence carcinogenesis.
Thus, epigenetic control of gene expression patterns in embryogenesis, stem cells and cancer
stem cells is a very important aspect for our understanding of human cancer development,
progression and therapy.
2. DNA methylation
According to the cancer stem cell theory, aberrant epigenetic changes may allow the trans‐
formation of stem cells in cancer stem cells [14].
Epigenetic regulation is realized by modifications that consist in four important mecha‐
nisms: DNA methylation, covalent modification of histone, nucleosome positioning and
changes of microRNA expression [23].
The biological process of DNA methylation is found in both eukaryotic and prokaryotic
cells and it can be involved in pathogenesis of several diseases, especially in cancer. This is
the most studied mechanism of epigenetic regulation, consisting in addition of a methyl
group to  the  carbon-5  position of  the  pyrimidine base  cytosine (C)  from the  nucleotide
structure  cytidine-5’-monophosphate  (CMP).  S-adenosyl-L-methionine  (SAM),  the  active
form of amino acid methionine, is the donor of methyl group resulting S-adenosylhomo‐
cysteine (SAH) [23].
In the mammalian genome, cytosine is coupled to guanine (G) to form a base pair, common‐
ly called cytosine-phosphate-guanine (CpG) dinucleotides. These dinucleotides are general‐
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ly methylated (CpG-poor regions) with the exception of GC-rich regions known as the CpG
islands [24, 25]. In human normal cells, it was observed that CpG islands are often hypome‐
thylated. In oncogenesis CpG islands suffer a hypermethylation process whereas the entire
pool CpG-poor regions are hypomethylated. DNA hypermethylation and hypomethylation
coexist in cancer cells, both processes demonstrating the importance of DNA methylation in
sustaining a normal gene expression pattern, genomic imprinting and silencing of genes in‐
volved in X-chromosome inactivation [1, 23, 26-29].
The DNA methylation process is catalyzed by specific DNA methyltransferase (DNMTs). In
human cells, five types of DNMTs enzymes have been reported [23, 30-33]. DNMT1 - DNA
(cytosine-5-)-methyltransferase 1, with role in regulation of normal tissue-specific methyla‐
tion; unusual methylation is related to the appearance of human cancer. DNMT2 has an un‐
certain role in human health and illness [34]. Grant A Challen et al. have shown that
DNMT3A and DNMT3B are implicated in embryonic stem cells differentiation [35] and
DNMT3L was reported to stimulate the activity of both DNMT3A and DNMT3B [36].
Figure 1. Methylation of cytosine. Cytosine methylation is one of the most extensive studied epigenetic processes. The
donor of the methyl group is the active form of methionine, S-adenosyl-L-methionine (SAM) and its addition to cyto‐
sine is realised at the carbon-5 position.
Over the past two decades, it was shown that DNA methylation plays a major role in the
regulation of the specific gene expression, during mitotic cell division, in the normal mam‐
malian cell, as well as in the stem cell [13, 37, 38].
A new hypothesize about tumorigenesis consists in dysregulation of the stem cell self-re‐
newal process. Dissemination of cancer stem cells is suggested to be induced by gene muta‐
tions and epigenetic modifications that may lead to metastasis [39].
DNA hypomethylation was found to activate cancer-germline (CG) genes or cancer-testis
(CT) gene family in tumours. The promoter region of CG genes is demethylated in a several
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tumour types, inducing genes transcriptional activation. In their study, Costa et al. hypothe‐
sized that expression of CG genes may be indispensable for stem cell biology [40, 41].
In addition to DNA hypermethylation and hypomethylation, a DNA demethylation process
was also described. While the active DNA demethylation process takes place in presence of
enzymes that catalyzed specific reactions, passive DNA demethylation can occur during
replication cycles and operates on DNA methyltransferases [42, 43]. Although the demethy‐
lation process is not fully elucidated, there are many studies showing transient involvement
of this process in various types of tumors, especially in advanced stages of their develop‐
ment [44]. The mechanism of DNA demethylation in cancer has been relatively less studied.
Until just a few years ago, scientists believed that the hypomethylation affects the whole ge‐
nome, randomly [45]. Dysregulations in embryonic normal development and also in normal
stem cells development, are generated by many signaling pathways, which can be associat‐
ed with cancer. Pathways signaling implicated in regulation of normal stem cell evolution
are also involved in stem cells self-renewal and carcinogenesis. The most common signaling
pathways in all processes mentioned are: Wnt, Notch and Sonic hedgehog (Shh) [46, 47].
Other signaling pathways reported to be involved in stem cell maintenance and pluripoten‐
cy are: TGF-beta, MET, MYC, EGF, p53, BMI, etc [5].
It is well-known that Wingless gene encodes the Wnt protein family that control the self–
renewal and tumorigenesis processes. Wnt protein is well preserved from Drosophila mela‐
nogaster and has an essential role during normal embryonic development. Wnt protein is a
part of a particularly signalling pathway, common to humans and Wnt protein dysregula‐
tion was reported to be involved in the development of tumors. It has been demonstrated
that some genes implicated in the Wnt signaling pathway, are inactivated by promoter hy‐
permethylation, generating lung metastasis from primary tumors [48].
The Notch signaling pathway was also suggested to have an important role in stem cell dif‐
ferentiation, proliferation and oncogenesis as well. Scientists have shown that in humans,
exist four Notch paralogs (i.e. Notch 1, 2, 3, and 4) and five ligands (i.e. Delta-like 1, 3, 4 and
Jagged 1 and 2). Activation of these Notch paralogs are found in stem cell self-renewal but
also in many types of cancers [49].
Some epigenetic changes like histone methylation and downregulation of gene expression,
which collaborate with the Notch developmental pathway during oncogenesis, were also
described [50].
3. Chromatin dynamic and histones modifications
Chromatin is represented by the mandatory association between nuclear DNA and proteins.
Chromatin presents different compression degrees during to cell cycles. It exists in two dif‐
ferent types: euchromatin and heterochromatin.
Euchromatin has more non repetitive DNA with prevailing of guanine and cytosine bases
and nonhistonic proteins; it is also less condensed and represents the active and transcrip‐
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tional part of the chromatin; it replicates early at the beginning of S faze, being R positive
bands from bands marked chromosomes [51].
Heterochromatin has more repetitive DNA with predominating adenine and thymine bases
and histones; it is very compact, genetically inactive, with late replication. Heterochromatin
functions are to stabilize the centromere and the telomeres of the chromosome, playing an
important role in meiosis and in cellular differentiation [52]. Heterochromatin is expressed
as constitutive or facultative chromatin. Constitutive heterochromatin is constantly found in
a condensed form. It doesn’t have functional genes and it is made of highly repetitive DNA
(satellite DNA).
Facultative heterochromatin is a chromosome region, densely packed and inactive in a par‐
ticular cells, having lost gene expression [53]. Both constitutive and facultative heterochro‐
matin, are regulated by the DNA silencing in the mammalian cells. Constitutive
heterochromatin is mandatory transcriptional silenced while facultative heterochromatin is
conditionally silenced [53].
Electronic microscope analysis shows a hierarchical system of chromatin fibers with differ‐
ent dimensions, made of DNA, histones and nonhistone proteins. The supramolecular or‐
ganization of DNA has four different levels. The first level is represented by four core
histone proteins (H2A, H2B, H3 and H4) which form an octamer wrapped around 1.75 times
by 146 base of DNA, making together nucleosomes [54]. Nucleosomes are linked by a short
fragment of free DNA (approximately 60 pairs of bases), closed tight by histone H1. The
compactness of DNA at this level is 10:1 [54]. Nucleosomes seem to be dynamic structures,
since they have to suffer structure modifications during transcription, replication or recom‐
bination of DNA. The second level of chromatin economy is represented by the chromatin
fiber of 30 nm, creating a solenoid aspect. A fundamental unit in the interphase, this chro‐
matin plays an important role by putting together regions of linear DNA, stimulating genic
interaction. The solenoid has a heterogeneous structure, characterized by an alternation of
spiral and not spiraled areas, creating a proper configuration for RNA polymerase action,
during transcription. The third level of chromatin organization results from creation of later‐
al loops of 300 nm diameter, attached to a protein nonhistonic matrix. At the beginning of
prophase, a matrix will be formed by a 20 times compaction a chromatid, the highest level of
chromatin organization [55]. So, the basic DNA will suffer an overall 10000 times compac‐
tion, being able to fit a small place into a nucleus. This conformation offers sterically occlu‐
sion for nucleosomes, which will be there for protected against nucleases cleavage, while the
linker DNA doesn’t have this kind of protection [56].
Many cancers are associated with translocations which can be explained by mutual rear‐
rangements due to misfit of two unrepaired double stranded breaks, determined by the
close proximity of some genetic regions, thus suggesting the dynamic properties of chroma‐
tin [57, 58]. Translocation that characterizes tumorigenesis may depend on the physical dis‐
tance between individual genetic elements. Chromatin is a dynamic structure, with its own
mobility that influences either gene regulation (local diffusion of chromatin) or genomic sta‐
bility (global chromatin immobility) [57]. In normal cells, as well as in tumor cells, there are
similar nuclear layers, defined as center of nucleus-to-locus distance, with a random distri‐
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bution of genetic loci inside it [59]. Polarization of some chromosomes, with their genes lo‐
cated in the interior of the nucleus and their centromeres located at the nuclear periphery,
along with all the other data already presented, strongly support the existing relation be‐
tween the chromatin pattern and tumor development, but still many aspects remain to be
proved.
The debate concerning chromatin remodeling as a cause or a consequence of tumorigenesis
is still on.
Many works indicate that DNA methylation and chromatin remodeling are in reciprocal
causal relationship: DNA methylation may cause chromatin modifications and specific chro‐
matin modification may induce DNA methylation [1]. Recent data suggest that chromatin
remodeling is a combination between a CIS effect determined by the action of a proximal
genetic sequence and a TRANS effect induced by sequence independent complexes, most
likely by ATP dependent nucleosomes remodeling complexes [60, 61].
Alu sequences are a class of repetitive DNA characterized by a pattern of CG dinucleotides
(CpG) repeating every 31-32 bases. They may modulate the nucleosome strength when the
CG elements are methylated. Thus, epigenetic nucleosomes within Alu sequences may have
methylation-dependent regulatory functions [62].
Emerging data are suggesting that since genome regulation might be influenced by nucleo‐
some positioning and their compositional modifications, nucleosomes are regulating the ini‐
tiation of transcription, therefore nucleosomes positioning is leading to cancer or
developmental effects [17]. Nucleosomes adopt preferential positions near promoter regions
and random positions inside genes [63]. Transcription needs exposed binding sites consist‐
ing in nucleosome free regions at the 5′ and 3′ ends of the genes, so any change in nucleo‐
some positioning at this level might determine gene activation [64, 65].
Nucleosome positioning is also influenced by another protein complex that activates or re‐
presses transcription through biochemical processes, such as octamer transfer, nucleosome
remodeling or nucleosome sliding: switch/sucrose nonfermentable (Swi/Snf) complex. It
consists in approximately 10 subunits of 2 MDa, with many variants of combinations, first
discovered in Saccharomyces cerevisiae [16, 66]. The multiple varieties of Swi/Snf complexes
exist in many cell types [67]. Swi/ Snf performs a crucial function in gene regulation and
chromosome organization by directly altering the contacts between nucleosomes and DNA
[68], using the energy of ATP hydrolysis [69]. The in vitro studies revealed that two subunits
of the complex, Brg1 or Brm, are able to remodel nucleosomes, with maximal results when
subunits BAF155, BAF170 and Ini1 presents a 2:1 stoichiometry relative to Brg1 [70]. The ac‐
tivity of chromatin remodelers appears to be gene specific [71]. The subunits of Swi/ Snf
complex seem to have a broad range of functions: BAF155 and BAF170 regulate the protein
levels and ensure framing functions for other SWI/SNF subunits [72, 73]; BAF53 is an actin
and β-actin related protein signaling, through phosphatidylinositol 4,5- bisphosphate, which
binds to Brg1, stimulating the binding to the actin filaments [74-76]; Ini1 is involved in rare
and aggressive pediatric cancers [77, 78] as well as in HIV 1 infection [79-81]. The role of
SWI/SNF components in cancer stem cells and tumor suppression is still vaguely under‐
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stood, but their transcriptional pathways are already described, including the cell cycle and
p53 signaling [82], insulin signaling [83], and TGFb signaling [84], or signaling through sev‐
eral different nuclear hormone receptors [85]. The biological roles of Swi/Snf components
and their involvement in human disease remain to be completed. It is also known that loss
of Snf2h impairs embryonic development and differentiation [86] and contributes to tumor
development [87]. These tumors are also characterized by polyploidy and chromosomal in‐
stability [88]. Since Swi/Snf complex plays also an important role in DNA double strand
brake repair, alteration of its function may lead to genomic instability [89]. Critical subunits
of Swi/Snf complex miss or are disrupted in approximately 17% of all human adenocarcino‐
mas [90]. Another tumor suppressor gene is Ikaros, a molecule that plays a central role in
lymphocyte development through its association with chromatin remodeling complexes
[91]. Fusion protein BCR-ABL from preB lymphoblastic leukemia mediates an aberrant
splicing of Ikaros, with consequences on cell differentiation [92].
Radiations have the ability to paradoxically induce or cure tumors. It seems that chromatin
structure might be influenced by UV and gamma radiation. To study the changes in chro‐
matin pattern under irradiation conditions, Fluorescence In Situ Hybridization (FISH), com‐
bined with high-resolution confocal microscopy has been used [93, 94]. FISH studies were
performed in leukemia cells for tumor suppressor gene TP53, revealing that TP53 genes are
getting closer to each other, as well with the nuclear center within 2 hours of exposure to
gamma-radiation, returning during the following 2 hours to its pre-irradiation conditions
[95, 96]. There is increasing evidence that CSCs have a higher intrinsic radioresistance than
non-CSC tumor cells [97], explaining the difference of CSCs and non-CSC in their response
to cancer therapy.
Such repressive complex for chromatin is “Nucleosome Remodeling and Histone Deacety‐
lase” (NuRD) [98], suggested to play a role in acute promyelocytic leukemia (APL) [99]. Hu‐
man APL is characterized by PML-RARa translocation, which represses gene transcription
through several distinct epigenetic mechanisms: DNA methylation, chromatin compaction,
heterochromatinization, histone deacetylation, histone modification. NuRD complex is
strongly implicated in the epigenetic silencing, by PML-RARa. Earlier findings regarding
carcinogenesis, such as the combination of both genetic and epigenetic factors, were con‐
firmed. in this case, PML-RARa oncogenic fusion protein recruiting, induces DNA hyperme‐
thylation [100] and result in blocking of hematopoietic differentiation [101].
Covalent modification of histones is an important mechanism, involved in the epigenetic
processes. Five types of histones are known to be involved in chromatin building: H1/H5,
H2A, H2B, H3, and H4 [15, 102]. In their structure, histones have three distinct domains: a
central globular conserved domain and two terminal domains; one short N-terminal tail and
one longer C-terminal tail [54].
Generally, histone modifications affect gene transcription, DNA replication and DNA repair
mechanisms. The post-translational modifications of the N-terminal tail domains include:
methylation, acetylation, phosphorylation, citrullination, ADP-ribosylation, sumoylation
and ubiquitination [18-20]. The most studied of these modifications are methylation and ace‐
tylation. Lysine residues acetylation in the histone H3 and H4 by histone acetyltransferase
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(HAT) and lysine 4 methylation in the histone H3 (H3K4me) by histone methyltransferase
(HMT), are generally correlated with active transcription of chromatin. In contrast, methyla‐
tion of lysine 9 and lysine 27 (H3K9, H3K27me) in the histone 3 have been reported as mark‐
ers in transcriptionally silenced-chromatin [21, 22].
During the last years, a major challenge in cancer biology is to elucidate how the histone
modifications in stem cells, influence carcinogenesis.
Histones methylation is a post translational modification that occurs at the lysine residues
and is considered a reversible process [103]. Transcriptional activation or repression, corre‐
lates with different degrees of methylation of histones. The binding of one to three methyl
groups at each lysine amino acid in the histone structure, give rise to unmethylated, mono‐
methylated, dimethylated and trimethylated degrees of methylation [104, 105]. The mono-
methylation state of histone has been reported to be associated with an open chromatin
structure that lead to transcriptional activation. In contrast, the trimethylation state was
shown to be associated with a condensed chromatin structure, which in turn inhibits tran‐
scription [106].
Some important  exceptions  from this  rule  have been reported by Strahl  BD et  al.,  they
showed that H3K4 histone methylation state (mono-, di-, or tri-methylated level) is invaria‐
bly associated with active chromatin, while H3K9 trimethylation can be connected to both
transcriptionally active and inactive chromatin [107].  To explain this  exception from the
general  rule,  Vakoc  et  al.,  described  a  mechanism  by  which  an  association  between
meH3K9 with  RNA polymerase  II  complexes  induces  chromatin  modification and tran‐
scriptional activation [108]. However, it is not fully understood why these markers differs
from the general rule.
The binding of the methyl group of each lysine 4, 36 or 79 in the histone 3 (H3K4, H3K36,
H3K79) and H4 (k20, H2BK5) induces trnascriptional activation. In contrast, the binding of
three methyl group of lysine 9, 27 in the histone 3 (H3K9, H33K27) AND h4k20 was show to
be associated with inhibiton of transcription [109, 110]. The histone modifications are arising
from the action of enzymes which are responsible for methylation/demethylation activity in
the pattern of histone H3 and H4. The enzymes involved in histone modifications are his‐
tone acetyltransferases (HATs) and histone deacetylases (HDACs), histona methyltransfer‐
ases (HMTs) and histone demethylases (HDMs). These enzymes add or remove acetyl or
methyl groups, respectively [111, 112]. Several enzymes, like histone methyltransferase
(HMTs), histone demethylases (HDMs) and histone deacetylases (HDACs), are connected
with each other to create a strong link between chromatin state and transcription.
In addition to changes in histone acetylation, widespread changes in histone methylation
patterns are described in cancer. Accordingly, in cancer, aberrant gene silencing was shown
to be associated with changes in H3K9 and H3K27 methylation patterns [113].
A recent analysis in the context of histone modifications in cancer, illustrates different sce‐
narios such as histone methylation and its consequences, describing the role of histone
methyltransferases (HMTs) and histone demethylation (HDMS) by adding or removing a
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methyl group. It has been reported that the level of transcriptional activation is largely
maintained by HMTs and HDMs which are involved in the histone methylation [103].
The histone lysine methyltransferase (HMT) that is responsible for the histone methylation,
has a catalytically active site known as SET domain, which is formed by de 130 amino acid
sequence. The major function of the SET domain is to modulate gene activity [114].
The binding of the methyl group at several lysine sites in histone H3 (H3K9, H3K27, H3K36,
H3K79) and loss of acetylated H4 lysine 16 and H4 lysine 20 trimethylation have been re‐
ported to be associated with changes that occur during tumorigenesis[115]. The enzymes
HDACs and HATs have been suggested to be responsible for these changes and are com‐
monly found to be altered in various forms of cancer [116].
Various observations suggest the presence of a novel chromatin pattern in embryonic stem
cell, which consists of lysine 27 and lysine 4 tri-methylation superposition, termed “bivalent
domains” [117].
The bivalent domains have been analysed by the genome mapping of histone methylation
profiles in embryonic stem cell and was reported to include both active and repressive chro‐
matin marks. Developmentally, the “bivalent domains” is responsible for maintaining epi‐
genomic plasticity, enabling embryonic stem cells to regulate gene expression [117].
Bivalency is lost during stem cell differentiation, allowing epigenetic plasticity and lineage
commitment. Epigenetic plasticity in association with bivalent gene promoters is suggested
to induce a transcriptionally repressive and permissive histone mark in embryonic stem
cells [117, 118].
In cancer, bivalency has been suggested to stigmatize specific genes for DNA methylation,
inducing aberrant reprogramming [119-121]. In analogy with embrionic stem cells, bivalent
gene promoters were reported to be DNA-methylated in cancer cells, suggesting the prove‐
nience of cancer cells from embryonic stem cells [122]. In absence of DNA methylation, the
repressive H3K27 trimethylation mark was also demonstrated to induce gene silencing in
cancer cells.
Chromatin regulating complexes are commonly observed in cancer, and is hypothesized to
involve multiple mechanisms, including DNA methylation and Polycomb repressive com‐
plexes (PRCs). Chromatin regulating complexes including two families of Polycomb repres‐
sive complexes (PRC1 and PRC1), mediate trimethylation on H3K27 in cancer cells [123,
124]. PRC2 complex has also been reported to intermediate H3K27 trimethylation in embry‐
onic stem cell [125].
4. miRNA and DNA methylation in cancer stem cells
MicroRNAs (miRNAs) was first discovered in 1993 by Victor Ambros, Rosalind Lee and
Rhonda Feinbaum. The recent definition of miRNA is: small non-coding RNA molecules
(21-24 nucleotides long), implicated in posttranscriptional gene expression, regulation by
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two different mechanisms: splitting and subsequent degradation of targeted RNAm or in‐
hibiting translation, both determining the stop or stimulation of cell reproduction [126-130].
However, the entire mechanism of miRNA is not yet fully understood [131, 132].
The study on Caenorhabditis elegans (C. elegans) has permitted the clonation of first miR‐
NA, lin-4 and let-7 and their targets [133, 134]. This study discovered that the gene lin-14
was able to transcribe a precursor that matured to a 22 nucleotide mature RNA, which con‐
tained sequences partially complementary to multiple sequences in the 3’ UTR of the lin-14
mRNA, ensuring inhibition of translation of lin-14 mRNA. In addition, in 2000, along with
the discovery that gene let-7 repressed the genes lin-41, lin-14, lin-28, lin-42 and daf12
mRNA during transition in developmental stages in C. Elegans, it was also established that
non-coding RNA identified in 1993, was part of a wider phenomenon [133].
More than 700 miRNAs have been identified in humans and over 800 more are predicted to
exist. These molecules have an important role in cellular physiological processes (e.g. cell cy‐
cle, cell proliferation, apoptosis, cell differentiation and development), by implication in
gene regulation; miRNA has been found to control about 30% of all human genes.
In human embryonic stem cells and the differentiated embryonic bodies, over 100 miRNAs
have been already described [101]. The self-renewal and pluripotency of embryonic stem
cells are regulated by an array of protein-coding genes in a regulatory circuitry [135], which
includes OCT4, SOX2, and KLF4 genes. Extensive studies have indicated the importance of
OCT4 in self-renewal and pluripotency of embryonic stem cells [136, 137]. Multipotent cell
lineages in early mouse development, have also been reported to be dependent on SOX2
function [138, 139] in the process of embryonic stem cells self-renewal and pluripotency. The
miRNA genes are also connected to the transcriptional regulatory circuitry of embryonic
stem cells [140] and are overexpressed in their differentiating processes.
The three key proteins of pluripotent cells, Oct4, Nanog and SOX2, and TCF3 were found in
the promoters of miRNA specific stem cells, but also in promoters of miRNA, which con‐
trols cell proliferation (mir 92 si let7g) and differentiation (e.g., mir-9 or mir-124a for neutral
line). OCT4 was reported to bind and repress miR-145 promoter in human embryonic stem
cells. On the other hand, inhibition of Oct 4 increases the activity of these miRNAs that in
turn inhibit the stem cell renewal.
miRNAs, occasionally causes DNA methylation of promoter sites and can regulate other
epigenetic mechanisms. An altered miRNA gene methylation patterns in human cancers
was reported to sustain in tumorigenesis. Half of these genes are associated with CpG is‐
lands and several  studies indicated that  miRNA gene methylation was often detectable,
both  in  normal  and  malignant  cells.  Recent  works  have  identified  many types  of  miR‐
NA, which allow cancer cells  to multiply indefinitely by avoiding natural  cellular aging
mechanisms,  thus  suggesting  a  close  relation  between cancer  development  and miRNA
expression [141].
There are several mechanisms which may lead to modification of mi RNA in cancer [142-145].
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• Chromosomal changes - quantitative gene changes have been identified in approximately
283 miRNA, determined by either loosing heterozigotism by the action of a suppressive
gene or by amplification of a chromosomal region of an oncogene either by chromosomal
ruptures or translocations [146];
• miRNA biosynthesis abnormalities, mainly represented by gene amplification for proteins as
Drosha (implicated in miRNA maturation process) or Ago2 (responsible for the interac‐
tion with target messengers);
• Epigenetic changes- recent data suggest the implication of DNA methylation in the disor‐
der of miRNA expression. Gene analysis for miRNA established that these genes are usu‐
ally associate with CpG islands and thus represent candidate targets of the DNA
methylation machinery. A high level of miRNA genes methylation exists both in normal
and malignant cells. Epigenetic changes of chromatin, for instance histone deacetylation,
cause important alteration of miRNA expression as well [141];
• miRNA as oncogenes or tumor suppressors - miRNA always acts as negative regulator of
gene expression. In cancer, miRNA were classifies as miRNA with oncogenic effect (onco‐
mirs) and miRNA with suppressor effect (supressor mirs) [147-149].
Oncogenic activity of miRNA, initially determined for mir-17-92 and mir-155, was further
sustained by the discovery of other potentially oncogenic miRNA [150]. Therefore it is logi‐
cal that this classification of miRNA in oncogenes or tumor supressor genes may facilitate
the identification of different tissues where they are expressed [151].
Embryonic stem cells gene expression of Oct4, Sox2, Klf4, and Nanog was observed in high‐
ly aggressive human tumors [152]. It has been reported that miR-200 known to mediate tran‐
scriptional repression, also play an important role in both cancer stem cells andembryonic
stem cells [153, 154].
Several miRNAs have been reported to be overexpressed in human cancer. The mir-17-92
polycistron (cluster) is overexpressed in B-cell lymphoma [155, 156] and in testicular germ
cell tumors miR-372 and miR-373 were identified as possible oncogenes [157].
Another theory supports the idea that some cancers such as Kaposi `s sarcoma, were in‐
duced by viral oncogenic miRNA [158]. It is clear that discovery of miRNA involvement
in cancer stem cells function will be a crucial step in elucidating the process of oncogen‐
esis [159].
5. Epigenetic targeting in cancer stem cells
Recently, several epigenetic drugs targeting epigenetic mechanisms have been tested in vivo
and in vitro. The epigenetic mechanisms comprise modifications of histones and DNA meth‐
ylation. Histone modifications includes several post translational modification of the: meth‐
ylation, acetylation, phosphorylation, ubiquitination, sumoylation; commonly found in
tumor cells. Thus, epigenetic modifications targeting is an important event in cancer thera‐
Methylation - From DNA, RNA and Histones to Diseases and Treatment164
py. Epigenetic targeting may be realized by two classes of substances with antitumor effect
in malignancies: the hypomethylating agents and histone deacetylase inhibitors [160].
5.1. Targeting DNA methylation
DNA methylation is the most studied epigenetic marker. Abnormal DNA methylation of
several regulatory genes is usually associated with cancer. The methylation process is rever‐
sible, therefore the reactivation of silenced genes can be realized using substances with hy‐
pomethylating activity [161].
The new development cancer therapies are based on molecules that can inhibit the classes of
DNA methyltransferases (DNMT), histone deacetylases (HDACs), histone acetyltransferases
(HATs) and new substances that target chromatin and nucleosome remodeling proteins.
DNMT inhibitors (DNMTi) can be natural or synthetic compounds [148, 162].
As mentioned before, DNMTs are enzymes that catalyze the reaction between methyl
groups and pyrimidine base cytosine. The methyl group donor is S-adenosyl-L-methionine
(SAM), which is the active form of amino acid methionine.
The DNA hypomethylating agents are divided into two categories: nucleoside analogs
drugs and non-nucleoside analogs drugs. The first description substances are 5-azacytidine
(azacitidine, VidazaTM) and 5-aza-2’-deoxycytidine (decitabine, DacogenTM) that have the





Figure 2. Nucleoside analog drugs. Their structure allows incorporation into the DNA and subsequent hypomethilation.
Other substances from this group are: 1-β-D-arabinosyl-5-azacytidine (fazarabine) [166], di‐
hydro-5-azacytidine (DHAC), 5-fluoro-2’-deoxycytidine (FCDR) and zebularine [163]. Incor‐
poration into the DNA structure of nucleoside analogs is facilitated by their similar chemical
structure.
5-azacytidine  is  used as  single-agent  therapy or  in  combination  with  other  therapies  in
treatment  of  myelodysplastic  syndromes  (MDS),  acute  myeloid  leukemias  (AML)  and
solid  tumor.  As  associated  substances  are  utilized  valproic  acid,  cytarabine,  entinostat,
etanercept etc [137, 164].
5-aza-2’-deoxycytidine (DAC) has benefited as monotherapy in myelodysplastic syndromes,
chronic myelomonocytic leukemia (CMML) and has been FDA approved on May 2006. The
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drug has been associated with: carboplatin useful in solid tumors treatment [167], valproic acid
in acute myeloid leukemias and advanced leukemia [168, 169], imatinib mesylate in chronic
myelogenous leukemia (CML) [170] and IL-2 in metastatic melanoma, renal carcinoma [171].
Zebularine (2-pyrimidone-1-β- D-riboside) is other nucleoside analog with hypomethylation
activity [172] and also implicated in tumor gene expression [173].
Figure 3. Structure of Zebularine. Zebularine is another nucleoside analog drug, with hypomethilation effect.
There are recent studies about another two molecules: NPEOC-DAC and SGI 110 (S110).
NPEOC-DAC is the result of chemical reaction between azacytosine molecule and 2-(p-ni‐
trophenyl) ethoxycarbonyl, with reported effect on DNA methyltransferases inhibition. By‐
un et al. demonstrated that NPEOC-DAC inhibited DNA methylation in two cell lines of
liver cancer. The authors, also showed that SGI 110 (S110) has a pronounced effect on DNA
methylation inhibition [174].
The non-nucleoside analogs category contains compounds with hypomethylation effect.
This group contains hydralazine (the widely known as vasodilatator), procainamide (anti-
arhythmic), RG108 and SGI-1027.
Physiologically, acetylation of chromatin is realized by specific enzymes - histone deace‐
tylases  and  acetyltransferases.  A  possible  change  in  their  normal  function  can  promote
tumors.
5.2. Targeting histone modification
At first glance, HDACs are enzymes that play a role in elimination of acetyl radical just from
lysine molecules of histones, but their actions is not limited to histones, they can also act on
non-histone proteins [175].
HDAC inhibitors are classified into four classes, based on their chemical structure: short-
chain fatty acids, hydroxamic acids, cyclic peptides, benzamides (hybrid molecules) [176].
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Figure 4. HDAC inhibitors. There are four classes of curently known HDAC inhibitors: short-chain fatty acids, hydroxa‐
mic acids, cyclic peptides, benzamides, with a great potential use as detection and prognosis markers.
Exemples of short-chain fatty acids are: sodium n-butyrate, sodium phenylacetate, phenyl‐
butyrate, valproate, substances that in millimolar concentrations are involved in inhibition
the growth of some carcinomas but their mechanism of action is not fully understood [163,
177-179].
One of the most studied agent from class of small fatty acids, is valproic acid (VPA), an anti‐
epileptic drug reported to target histone deacetylase. Numerous research studies in vitro
demonstrated that VPA was implicated in hyperacetylation of histones H3 and H4 and also
in vivo tests confirmed the drug inhibiting action of HDACs. VPA antitumor activity was de‐
manstrated by: cell growth inhibition, apoptosis inducing, antimetastatic and antiangiogene‐
sis effect, etc. These benefits lead to FDA approving of VPA [14, 180].






Figure 5. Structure of valproic acid. Valproic acid is a small fatty acid commonly used as an antiepileptic drug, but with
recently emerged antitumor effects.
The class of hydroxamic acids include synthesized compounds such as: belinostat, panobino‐
stat, vorinostat (SAHA) etc. Belinostat and panobinostat, have been used in clinical trials to treat
solid tumors and blood malignancies [181-183]; MDL and CML [184-186], vorinostat (SAHA)
that was approved by FDA for the treatment of chronic T-cell lymphoma (CTCL) and used in
clinical trials for hematologic malignancies, mesothelioma, breast and ovarian cancer, etc [175].
A natural compound from cyclic peptides class is romidepsin, also known as Istodax
(FK228), which was clinical tested in various lymphomas. The drug was shown to induce
apoptosis in different tumor cell lines, due to blocking of HDACs [187].
Hybrid molecules (i.e. benzamides) includes two synthetic compounds: Entinostat (MS-275)
and Mocetinostat (MGCD 0103). The mechanism by which Entinostat induced cytotoxic ef‐
fect on tumor cells was suggested to be due to the upregulation of some tumor suppressor
genes (p21]. Both Entinostat and Mocetinostat are currently approved by the FDA and are
used in cancer treatment. Entinostat is used in the treatment of blood and lung tumor [181,
183] and Mocetinostatin in the treatment of chronic lymphocytic leukemia (CLL) [175].
HATs are a class of enzymes discovered twenty years ago, enzymes with demonstrated role
in gene transcription [188]. HATs have been reported to be implicate in numerous types of
diseases (i.e. viral infection, respiratory maladies, cancer etc). It has been suggested that the
HATs enzymes may be used as biological markers for cancer prediction or recurrence [14].
Four families of HATs are known that share primary-structure homology: GNAT (Gcn5-re‐
lated N-acetyltransferase), p300/CBP and MYST, Rtt109 [189]. The HAT enzymes have vari‐
ous chemical structure and their classification is still unclear.
Histone methylation process plays an important task in epigenetic regulation, which lead to
synthesizing of new target drugs for cancer therapy [163].
Researchers describe a class of enzymes called histone methyltransferases. This class of en‐
zymes includes lysine methyltransferases and arginine methyltransferases, both of them
linked to many types of cancer.
There are 8 known lysine methyltransferases (KMT1-8) with suggested role in the epigenetic
gene silencing in malignancies like: prostate, liver, colon, breast cancer [190, 191].
Few of the many types of arginine methyltransferases (PRMTs), are also closely linked to
cancer [191].
Thus, the importance of DNMTs and HDACs, two classes of enzymes involved in epigenetic
targeted therapy of malignant diseases, is obvious. The enzymes implicated in histone meth‐
ylation and demethylation are mainly attractive as validated targets for cancer therapy.
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6. Conclusions and perspectives
Epigenetic is a heritage mechanism involved in the process of stem cells differentiation to
more specialized cells. According to the cancer stem cell model, dysregulation of epigenetic
mechanisms (i.e. DNA methylation and histone modification) in pluripotent stem cells ena‐
ble their transformation in cancer cells with high proliferation rates and poor prognosis.
DNA methylation is considered the most largely studied part of the epigenetic, but recent
works associate the methylation with other epigenetic changes, such as histone modifica‐
tions, chromatin remodeling and microRNA, suggesting a reciprocal relationship between
them in cancer cells. The similarities between chromatin regulation process in stem cells and
cancer cells have been mentioned in several studies.
It is therefore important to understand the epigenetic alterations that take place in cancer
cells compared with normal cells and the importance of these modifications in carcinogene‐
sis, according to the cancer stem cell theory. In addition, it is very useful to understand the
potential of epigenetic marks in designing more effective treatment strategies that specifical‐
ly target cancer stem cells.
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